Similarly, a recent meta-analysis that confirmed the safety and efficacy of GLP-1 receptor agonists, including liraglutide, in improving glycemic control among obese pediatric patients and/or those with type 2 diabetes (13). This evidence concerns the gene GLP1R and type 2 diabetes mellitus.